Emergent BioSolutions Inc (EBS.N)
EBS.N on New York Stock Exchange
17.73USD
10:44am EDT
17.73USD
10:44am EDT
Price Change (% chg)
$0.04 (+0.23%)
$0.04 (+0.23%)
Prev Close
$17.69
$17.69
Open
$17.80
$17.80
Day's High
$17.80
$17.80
Day's Low
$17.66
$17.66
Volume
8,183
8,183
Avg. Vol
50,833
50,833
52-wk High
$18.25
$18.25
52-wk Low
$12.50
$12.50
About
Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and... (more)
Overall
| Beta: | -0.03 |
| Market Cap (Mil.): | $638.99 |
| Shares Outstanding (Mil.): | 36.12 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| EBS.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 28.99 | 37.93 | 37.76 |
| EPS (TTM): | 0.61 | -- | -- |
| ROI: | 3.60 | 19.48 | 18.76 |
| ROE: | 5.27 | 20.17 | 19.59 |
RPT-BRIEF-Emergent Biosolutions to expand clinical trial of TRU-016 and rituximab
April 5 - April 5 - Emergent Biosolutions Inc : * To expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment and encouraging early clinical data * Source text for Eikon * Further company coverage
Competitors
| Price | Change | |
|---|---|---|
| Merck & Co., Inc. (MRK.N) | $48.15 | -0.02 |
| GlaxoSmithKline plc (GSK.L) | 1,706.00p | +22.00 |
| Sanofi SA (SASY.PA) | €76.37 | -3.80 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Human Genome Sciences (HGSI.OQ) | -- | -- |
| Bavarian Nordic A/S (BAVA.CO) | kr.60.50 | +0.50 |
| PharmAthene, Inc. (PIP.A) | $1.68 | -0.09 |
| Pfizer Inc. (PFE.N) | $29.16 | -0.07 |
| Johnson & Johnson (JNJ.N) | $93.84 | +0.34 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: MacroRisk Analytics/EconomicInvestor
|
$15.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

